

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10026992
Filing Date	2001-12-19
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Deepak Rao
Attorney Docket Number	VPI/00-130-4 US

U.S. PATENTS[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6558657	B1	2003-05-06	Mandeville, III et al.	
	2	6495582	B1	2002-12-17	Hale et al.	
	3	6528509	B1	2003-03-04	Hale et al.	
	4	57101158		1998-01-20	Myers et al.	
	5	6838464	B2	2005-01-04	AstraZeneca AB	
	6	6593326	B1	2003-07-15	AstraZeneca AB	

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)**U.S. PATENT APPLICATION PUBLICATIONS**[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
-------------------	---------	--------------------	------------------------	------------------	---	--

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10026992
Filing Date	2001-12-19
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Deepak Rao
Attorney Docket Number	VP/00-130-4 US

1	20030078166	A1	2003-04-24	Davies et al.	
2	20050004110	A1	2005-01-06	Bebbington et al.	
3	20030073687	A1	2003-04-17	Bebbington et al.	
4	20030064981	A1	2003-04-03	Knegt et al.	
5	20030055044	A1	2003-03-20	Davies et al.	
6	20030083327	A1	2003-05-01	Davies et al.	
7	20040097501	A1	2004-05-20	Bebbington et al.	
8	20030078275	A1	2003-04-24	Bebbington et al.	
9	20030055068	A1	2003-03-20	Bebbington et al.	
10	20030036543	A1	2003-02-20	Bebbington et al.	
11	20040002496	A1	2004-01-01	Bebbington et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10026992
Filing Date	2001-12-19
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Deepak Rao
Attorney Docket Number	VP/00-130-4 US

12	20030225073	A1	2003-12-04	Bebbington et al.	
13	20040009974	A1	2004-01-15	Bebbington et al.	
14	20030199526	A1	2003-10-23	Choquette et al.	
15	20030092714	A1	2003-05-15	Cao et al.	
16	20040229875	A1	2004-11-18	Cao et al.	
17	20030096816	A1	2003-05-22	Cao et al.	
18	20040023963	A1	2004-02-05	Cao et al.	
19	20030207873	A1	2003-11-06	Harrington et al.	
20	20030096813	A1	2003-05-22	Cao et al.	
21	20030144309	A1	2003-07-31	Choon-Moon	
22	20040009996	A1	2004-01-15	Moon et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10026992
Filing Date	2001-12-19
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Deepak Rao
Attorney Docket Number	VPI/00-130-4 US

23	20030171389	A1	2003-09-11	Bemis et al.	
24	20040029857	A1	2004-02-12	Hale et al.	
25	20050234059	A1	2005-10-20	Hale et al.	
26	20040097531	A1	2004-05-20	Ledeboer et al.	
27	20030022885	A1	2003-01-30	Bebbington et al.	
28	20030004161	A1	2003-01-02	Bebbington et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0019811	EP	A1	1980-12-10	Ciba-Geigy AG		<input type="checkbox"/>
	2	2052487	GB	A	1981-01-28	Ciba-Geigy AG		<input type="checkbox"/>
	3	06-65237	JP	A	2007-10-25	Nissan Chem. Ind., Ltd.		<input checked="" type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10026992
Filing Date	2001-12-19
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Deepak Rao
Attorney Docket Number	VP/00-130-4 US

4	10-130150	JP	A	1998-05-19	Dainippon Pharmaceutical Co., Ltd.	<input checked="" type="checkbox"/>
5	2458965	DE	A1	1976-06-16	Bayer AG	<input type="checkbox"/>
6	2000-026421	JP	A	2000-01-25	Kumiai Chem Ind. Co. Ltd.	<input checked="" type="checkbox"/>
7	9918781	WO	A1	1999-04-22	Cytovia, Inc.	<input type="checkbox"/>
8	9965897	WO	A1	1999-12-23	Chiron Corporation	<input type="checkbox"/>
9	0218346	WO	A1	2002-03-07	Pfizer Products Inc.	<input type="checkbox"/>
10	0125220	WO	A1	2001-04-12	Kinetix Pharmaceuticals Inc.	<input type="checkbox"/>
11	0021955	WO	A1	2000-04-20	AstraZeneca AB	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Alonso, M. et al., "GSK-3 Inhibitors: Discoveries and Develoments", Current Medicinal Chemistry, 11, 755-763 (2004).	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10026992
Filing Date	2001-12-19
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Deepak Rao
Attorney Docket Number	VP/00-130-4 US

2	Anonymous, "Vertex Inhibitors of Aurora-2, glycogen synthase kinase-3 and Src Kinase", Expert Opin. Ther. Patents, 14(3): 439-443 (2004).	<input type="checkbox"/>
3	Baig, G.U. et al., "Triazines and Related Products. Part 28' Conversion of 3-Aryl-1-(2-cyanophenyl) triazines into 3-Arylquinoxaline-4(3H)-ones with Formamide" J. Chem. Soc. Perkin Trans. I, 3765-2766 (1984).	<input type="checkbox"/>
4	Bischoff, J.R., et al., "A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers", The EMBO Journal, 17(11): 3052-3065 (1998).	<input type="checkbox"/>
5	Bischoff, J.R., et al., "The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis", CELL BIOLOGY, 9, 454-459 (1999).	<input type="checkbox"/>
6	Brunswick, D.J. et al., "Cyclic Amidines. Part XXII. Novel Isomerism of Disubstituted Tricycloquinazolines and Molecular Orientations in Carcinogenesis", J. Chem. SOC. (C), 2641-2647 (1970).	<input type="checkbox"/>
7	Wolff, M.E., "Burger's Medicinal Chemistry and Drug Discovery," 5th ed., Vol. 1: Principles and Practice, 975-977 (1995).	<input type="checkbox"/>
8	Cohen, P. et al., "The renaissance of GSK3," Nat. Rev. Mol. Biol., 2, 769-776 (2001).	<input type="checkbox"/>
9	Eldar-Finkelman, H. et al., "Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment," Expert Opinion on Investigational Drugs, 12(9): 1511-1519 (2003).	<input type="checkbox"/>
10	Harrington, E.A. et al., "VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo," Nat. Med., 10(3): 262-267 (2004).	<input type="checkbox"/>
11	Heutink, P., "Untangling tau-related dementia", Hum. Mol. Genet., 9(6): 979-986 (2000).	<input type="checkbox"/>
12	Nigg, E.A., "Mitotic Kinases as Regulators of Cell Division and its Checkpoints," Nat. Rev. Mol. Cell Biol., 2: 21-32 (2001).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10026992
Filing Date	2001-12-19
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Deepak Rao
Attorney Docket Number	VP/00-130-4 US

13	Traxler, P. et al., "Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines," J. Med. Chem., 40, 3601-3616 (1997).	<input type="checkbox"/>
14	CAPLUS listing Accession No. 1994:292136, Nakajima, Y. et al., "Pyrazoles agricultural and horticultural bactericides," JP 06065237 (1994).	<input type="checkbox"/>
15	DATABASE CA "Online!" Chemical Abstract Service, Columbus, OH, US; Kelarev, V.I. et al., "Synthesis of amino derivatives of 1,3,5-triazine containing 1,3,4-thiadiazole fragments," Database Accession No. 1998:69514 XP002242653 abstract & IZVESTIYA VYSSHIKH UCHEBNKH ZAVEDENII, KHIMIYA I KHIMICHESKAYA TEKHOLOGIYA, 40(5): 27-32 (1997).	<input type="checkbox"/>
16	Chalmers, D.T. et al., "Corticotrophin-releasing factor receptors: from molecular biology to drug design," TiPS, 17, 769-776 (2001).	<input type="checkbox"/>
17	Kim et al., "GSK3, a master switch regulating cell-fate specification and tumorigenesis," Current Opinion in Genetics & Development, 10:508-514 (2000).	<input type="checkbox"/>
18	Lyrer, P., Schweiz. Med. Woohen Schr., 124(45); 2005-2012 (1994).	<input type="checkbox"/>
19	Douglas, et al., "Introduction to Viral Disease, Cecil Textbook of Medicine, 20th Edition, Vol. 2, 1739-1749 (1996).	<input type="checkbox"/>
20	Banker, G.S. et al., "Modern Pharmaceutics", 451 & 596, 3rd ed., Marcel Dekker, New York (1996).	<input type="checkbox"/>
21	Lovestone, S. et al., "Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells", Curr. Biol., 4(12), 1077-86 (1994).	<input type="checkbox"/>
22	Ivashchenko A. V. et al., "Synthesis and Study of Heteroaromatic Ligands Containing a Pyrimidine Ring", Khim. Geterotsikl. Soedin., (12), 1673-7, (1980) (in English).	<input type="checkbox"/>
23	Brownlees, J. et al., "Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta transgenes", Neuroreport., 8(15), 3251-5 (1997).	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10026992
Filing Date	2001-12-19
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Deepak Rao
Attorney Docket Number	VP/00-130-4 US

24	Biagi, G. et al., "Synthesis of 4,6 Disubstituted and 4,5,6-Trisubstituted-2-Phenyl-pyrimidines and Their Affinity Towards A1 Adenosine Receptors", <i>Farmaco.</i> , 52(1), 61-65 (1997).	<input type="checkbox"/>
25	Ali, N.M. et al., "Palladium-Catalyzed Cross Coupling Reactions of Arylboronic Acids with Pi-Deficient Heteroaryl Chlorides" <i>Tetrahedron</i> , 48 (37), 8117-8126 (1992).	<input type="checkbox"/>
26	Zhang, Z. et al., "Destabilization of β catenin by mutations in presenilin-1 potentiates neuronal apoptosis", <i>Nature</i> , 395, 698-702 (1998).	<input type="checkbox"/>
27	Takashima, K. et al., "Tau Protein Kinase I is Essential for Amyloid β -Protein-Induced Neurotoxicity", <i>PNAS</i> 90, 7789-7793 (1993).	<input type="checkbox"/>
28	Pei, J. et al., "Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Brain", <i>J. Neuropathol. Exp.</i> , 56, 70-78 (1997).	<input type="checkbox"/>
29	IUPAC Compendium of Chemical Terminology on a definition of "aliphatic compounds" found from http://www.chemsoc.org/chembytes/goldbook/index.htm (last visited on November 18, 2007).	<input type="checkbox"/>
30	Glossary of Class Names of Organic Compounds and Reactive Intermediates Based on Structure found from http://www.chem.qmul.ac.uk/iupac/class/index.html (last visited on November 18, 2007).	<input type="checkbox"/>
31	Nomenclature found from http://www.cem.msu.edu/~reusch/VirtualText/nomen1.htm (last visited on November 18, 2007).	<input type="checkbox"/>
32	Bokemeyer, D. et al., "Multiple intracellular MAP kinase signaling cascades", <i>Kidney Int.</i> , 49, 1187-1198 (1996).	<input type="checkbox"/>
33	Anderson, N.G. et al., "Multiple intracellular MAP kinase signaling cascades", <i>Nature</i> , 343, 651-653 (1990).	<input type="checkbox"/>
34	Crews, C.M. et al., "The Primary Structure of MEK, a Protein Kinase That Phosphorylates the ERK Gene Product", <i>Science</i> , 258, 478-480 (1992).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10026992
Filing Date	2001-12-19
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Deepak Rao
Attorney Docket Number	VP/00-130-4 US

35	Bjorbaek, C. et al, "Divergent Functional Roles for p90rsk Kinase Domains", J. Biol. Chem., 270(32), 18848-18552 (1995).	<input type="checkbox"/>
36	Rouse, J. et al., A Novel Kinase Cascade Triggered by Stress and Heat Shock That Stimulates MAPKAP Kinase-2 and Phosphorylation of the Small Heat Shock Proteins", Cell, 78, 1027-1037 (1994).	<input type="checkbox"/>
37	Raingeaud, J. et al., MMK3- and MMK6-Regulated Gene Expression Is Mediated by p38 Mitogen-Activated Protein Kinase Signal Transduction Pathway", Mol. Cell. Biol., 16, 1247-1255 (1996).	<input type="checkbox"/>
38	Chen, R.H. et al., "Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase", Proc. Natl. Acad. Sci. USA, 90, 10952-10956 (1993).	<input type="checkbox"/>
39	Moodie, S.A. et al., "Complexes of Ras-GTP with Raf-1 and Mitogen-Activated Protein Kinase Kinase", Science, 260 (5114), 1659-1661 (1993).	<input type="checkbox"/>
40	Frey, R.S. et al., "Involvement of Extracellular Signal-regulated Kinase 2 and Stress-activated Protein Kinase/Jun N-Terminal Kinase Activation by Transforming Growth Factor β in the Negative Growth Control of Breast Cancer Cells", Cancer Res., 57, 628-633 (1997).	<input type="checkbox"/>
41	Sivaraman, V.S., et al., "Hyperexpression of Mitogen-activated Protein Kinase in Human Breast Cancer", J. Clin. Invest., 99(7), 1478-1483 (1997).	<input type="checkbox"/>
42	Whelchel, A. et al., "Inhibition of ERK Activation Attenuates Endothelin-stimulated Airway Smooth Muscle Cell Proliferation", Am. J. Respir. Cell Mol. Biol., 16, 589-596 (1997).	<input type="checkbox"/>
43	Yuan, Z.Q. et al., "Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer", Oncogene, 19, 2324-2330 (2000).	<input type="checkbox"/>
44	Namikawa, T. J., et al., "Akt/Protein Kinase B Prevents Injury-Induced Motoneuron Death and Accelerates Axonal Regeneration", J. of Neuroscience, 20(8), 2875-2986 (2000).	<input type="checkbox"/>
45	Molina, T.J. et al., "Profound block in thymocyte development in mice lacking p56lck", Nature, 357, 161-164 (1992).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10026992
Filing Date	2001-12-19
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Deepak Rao
Attorney Docket Number	VP/00-130-4 US

46	Kimura, M. et al., "Cell Cycle-dependent Expression and Centrosome Localization of a Third Human Aurora/Ipl1-related Protein Kinase, AIK3", J. Biol. Chem., 274(11), 13766-13771 (1997).	<input type="checkbox"/>
----	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Deepak Rao/	Date Considered	05/12/2008
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/